Phase II trials of second-generation antisense cancer drug planned following successful early study

September 29, 2004

Geneva, Switzerland: Phase II trials of the first second-generation antisense cancer drug to be used in patients are soon to be underway in the wake of a successful Phase I study, which has demonstrated that the new drug blocks its target gene in exactly the way it is designed to do.

In the Phase I study the drug - OGX-011* - inhibited the production of clusterin, a protein that protects cell survival and is widely distributed in body tissue. Clusterin is implicated in a range of activities, including apoptosis (programmed cell death). When it is over-produced, as it is many major cancers, clusterin can stop cancer cells from dying and counters the effectiveness of chemotherapy, hormone treatment and radiotherapy.

Dr. Kim Chi, assistant professor of medicine at the University of British Columbia and medical oncologist at the BC Cancer Agency in Canada, told the EORTC-NCI-AACR[1] Symposium on Molecular Targets and Cancer Therapeutics in Geneva today (Wednesday 29 September) that the Phase I trial was unique in that the clinical research team was able to demonstrate that the target clusterin was inhibited by OGX-011 in patients' cancers in a dose dependent way.

"This means that the drug is doing what it is supposed to be doing - something that we can't always say about targeted therapeutics - and we were able to identify a biologically active dose," he said.

Antisense drugs work by inhibiting the production of a protein from a specifically targeted gene. As a second-generation antisense drug, OGX-011 is an advance on earlier ones in that the molecules have a longer tissue half life and are potentially more potent. Pre-clinical studies had shown that blocking the production of clusterin with OGX-011 impairs a cancer cell's survival mechanism and enhances the effectiveness of standard chemotherapy, radiation and hormone therapy.

Twenty-five patients with localised prostate cancer that was to be removed by surgery were given escalating doses in the Phase I trial, which was coordinated by the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) and funded by the U.S. Department of Defense Army Medical Research and Material Command Prostate Cancer Research Program.

Two conventional prostate cancer hormone therapies, buserelin and flutamide, were given alongside OGX-011. Post surgery analysis of the patients' prostate cancers showed that the higher the dose of OGX-011 given, the lower clusterin levels were within the cancer cells. At the highest dose given of 640mg the clusterin messenger RNA (mRNA) was down to a mean 8% level as compared to historical controls. The drug was well tolerated by patients.

Said Dr. Chi: "We designed the Phase I trial in such a way that we could identify the biologically active dose in the tumour tissue. Being able to identify the active dose in this way gives us confidence that the Phase II dose of the drug that we have selected is the appropriate one. The Phase II studies are of a more conventional design, looking at response rates from OGX-011 plus standard chemotherapy in patients with metastatic hormone refractory prostate, breast and lung cancer. Phase II breast and prostate studies will begin near the end of the year, and a Phase I lung cancer trial started this month. The trials will recruit around 40 to 50 patients each and accrual should be complete in around six to 12 months, with results soon after that.

"Of course, it is still early days, but we are optimistic. The drug worked well in animal models and we hope that we will be able to see benefits akin to some of the other targeted therapies now in use."
-end-
Abstract no: 29

* OGX-011 (OncoGenex Technologies Inc., Vancouver, Canada, Isis Pharmaceuticals, Inc., Carlsbad, CA).

[1] EORTC [European Organisation for Research and Treatment of Cancer]; NCI [National Cancer Institute]; AACR [American Association for Cancer Research]

Further information
Margaret Willson (media information officer)
Tel: 44-153-677-2181
Mobile: 44-797-385-3347
Email: m.willson@mwcommunications.org.uk

From 16.00 hrs CET Monday 27 September to 17.00 hrs CET Friday 1 October contact EORTC-NCI-AACR symposium press office:
Tel: 41-22-761-2205
Fax: 41-22-761-2211

European Organisation for Research and Treatment of Cancer

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.